The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Eli Lilly reported a 48% surge in Q2 revenue to $23.0 billion, driven by robust demand for Mounjaro and Zepbound. Following this performance, the company raised its full-year financial guidance and its 2026 outlook, citing expanded Medicare access. Additionally, the company plans to seek regulatory approval for retatrutide by 2027. Other market updates included a 1.4% net sales increase for Utz Brands and tightened revenue guidance from Eos Energy Enterprises.